All In Biotech

NDA 050641 · Chartwell Rx

Monodox

Doxycycline · Oral · Tetracycline-class Drug

Last checked: Nov 19, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

Dec 29, 1989

Approved uses

1

Original approval plus efficacy supplements

Registered trials

428

84 Phase 3, 42 recruiting

FAERS reports

53,422

41,375 serious, 4,956 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 24, 2026.

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline capsules and other antibacterial drugs, doxycycline capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (ornithosis) caused by Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis. Nongonococcal urethritis caused by Ureaplasma urealyticum. Relapsing fever due to Borrelia recurrentis. Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 29, 1989 Original approval · Type 3 - New Dosage Form
4 products under this application
  • MONODOX · DOXYCYCLINE EQ 75MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • MONODOX · DOXYCYCLINE EQ 100MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • MONODOX · DOXYCYCLINE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • MONODOX · DOXYCYCLINE EQ 50MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxycycline" as an intervention, any sponsor and status, largest first.

All 428 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,220
  • off label use3,727
  • nausea3,691
  • fatigue3,327
  • dyspnoea3,154
  • rash3,090
  • diarrhoea3,040
  • headache2,878
  • pain2,867
  • vomiting2,840
  • malaise2,385
  • condition aggravated2,196

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004221
2005316
2006318
2007351
2008418
2009681
2010930
20111,144
20121,301
20131,415
20141,657
20152,028
20162,664
20172,772
20183,495
20194,345
20204,138
20213,627
20223,919
20234,687
20244,930
20254,749
20263,316

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,510 on PubMed

Sponsor: Chartwell Rx

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.